HealthTree

Your Feed

Filter by

See content from

Back to the latest

What Factors Make MGUS Progress Faster?

What Factors Make MGUS Progress Faster? image

Venetoclax Added to Standard Chemotherapy Shows High Response in Newly Diagnosed AML

Venetoclax Added to Standard Chemotherapy Shows High Response in Newly Diagnosed AML image

How HealthTree Cure Team Volunteers Are Driving Change in Blood Cancer Care

How HealthTree Cure Team Volunteers Are Driving Change in Blood Cancer Care image

Isatuximab combination (Isa-VRd) for Multiple Myeloma: Key Findings from the IMROZ Study

Isatuximab combination (Isa-VRd) for Multiple Myeloma: Key Findings from the IMROZ Study image

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions image

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions

01:00PM - 02:00PM EDT

Watch Recording

What Is Olanzapine and How Is It Used to Treat Nausea Caused by Chemotherapy

What Is Olanzapine and How Is It Used to Treat Nausea Caused by Chemotherapy image

Improve Well-Being with Tai Chi and Qigong While Living with Blood Cancer

Improve Well-Being with Tai Chi and Qigong While Living with Blood Cancer image

Aromatherapy for Nausea: Four Essential Oils to Try

Aromatherapy for Nausea: Four Essential Oils to Try image

Avoiding Costly Mistakes in Medicare, Understanding Medicaid Changes

Avoiding Costly Mistakes in Medicare, Understanding Medicaid Changes image

How Demographics and Income Affect Survival in MDS

How Demographics and Income Affect Survival in MDS image

Blenrep Is Now Approved in Canada and Europe for Relapsed/Refractory Multiple Myeloma

Blenrep Is Now Approved in Canada and Europe for Relapsed/Refractory Multiple Myeloma image

Real-World Outcomes of CPX-351 For High-Risk AML Patients

Real-World Outcomes of CPX-351 For High-Risk AML Patients image

New Treatment Option for Pre-Fibrotic and Low-Risk Myelofibrosis

New Treatment Option for Pre-Fibrotic and Low-Risk Myelofibrosis image

Iberdomide Combination Study Results for Transplant Ineligible Myeloma Patients

Iberdomide Combination Study Results for Transplant Ineligible Myeloma Patients image

Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials

Latest in Relapsed/Refractory Amyloidosis Research: Early Results of CAR-T and Bispecific Antibody Clinical Trials image

Imetelstat Updates For Lower-Risk MDS

Imetelstat Updates For Lower-Risk MDS image

Living with Polycythemia Vera (PV): Dana Turner Shares How Self-Advocacy Has Improved Her Care

Living with Polycythemia Vera (PV): Dana Turner Shares How Self-Advocacy Has Improved Her Care image

How Race, Income, and Access to Care impact AML Outcomes

How Race, Income, and Access to Care impact AML Outcomes image

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma

Belantamab Combination May Offer an Alternative to CAR-T for Relapsed/Refractory Myeloma image

Thumbnail for Promising Results for Menin Inhibitors in Combination with 7+3 in AML | Amer Zeidan, MD | #EHA2025

Playlist: EHA 2025

Promising Results for Menin Inhibitors in Combination with 7+3 in AML | Amer Zeidan, MD | #EHA2025

Video details & playlist

Thumbnail for Imetelstat and Luspatercept in MDS Anemia | Valeria Santini, MD | #EHA2025

Playlist: EHA 2025

Imetelstat and Luspatercept in MDS Anemia | Valeria Santini, MD | #EHA2025

Video details & playlist

Thumbnail for Treatment of Patients with High-Risk MDS | Maher Salamoon, MD | #EHA2025

Playlist: EHA 2025

Treatment of Patients with High-Risk MDS | Maher Salamoon, MD | #EHA2025

Video details & playlist

Thumbnail for When should bone marrow biopsies be repeated?

Playlist: All About Bone Marrow Biopsies

When should bone marrow biopsies be repeated?

Video details & playlist

Inqovi: An All-oral Therapy Being Studied for AML Patients

Inqovi: An All-oral Therapy Being Studied for AML Patients image

More from HealthTree